Skip to content

GLUE · Monte Rosa Therapeutics, Inc.

Healthcare · −3.8% on Oct 16

☆ Add to watchlist

Updated Oct 17 · 10 feeds behind: Big-holder filings, 4 days, and 9 more · Every feed →

On this page

The market view

Price chart

The interactive GLUE chart (by TradingView) loads here.

Our take

None of our tested rules has picked GLUE yet.

The 0–100 score for GLUE
Members see one number for how strongly these rules agree on GLUE, and the day each rule fired. Better-tested rules count more, and so do different kinds of filings that point the same way.
See pricing →
Already a member? Sign in

Compare with this company’s history

Is disclosure activity unusual?

See how many different insiders or members of Congress reported purchases or sales of GLUE. Each bar covers 28 days, by disclosure date. Several trades by one person count once in each group and period.

Latest period: Sep 26, 2026–Oct 23, 2026 · UTC dates · today is excluded

Insider sales

Short history

Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual.

Latest 28 days
1
Earlier median
0
Earlier range
0–3
Distinct filers per 28 daysScale: 0–4
Oct 25, 2025Oct 23, 2026
Earlier periodsLatest 28 daysEarlier median 0Limited or missing history

Who appears in the latest period?

Up to three filers; one example disclosure each.

Inspect this period’s filings

The history behind this view

First stored company disclosure: Jun 18, 2026. Newest disclosure across this feed: Oct 16, 2026.

Earlier periods in the comparison: 3. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.

Exact counts, dates and filings for all four categories
Insider purchases · Short history

Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–0.

Insider purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 25, 2025–Nov 21, 2025—Unavailable
Nov 22, 2025–Dec 19, 2025—Unavailable
Dec 20, 2025–Jan 16, 2026—Unavailable
Jan 17, 2026–Feb 13, 2026—Unavailable
Feb 14, 2026–Mar 13, 2026—Unavailable
Mar 14, 2026–Apr 10, 2026—Unavailable
Apr 11, 2026–May 8, 2026—Unavailable
May 9, 2026–Jun 5, 2026—Unavailable
Jun 6, 2026–Jul 3, 20260Partial; excluded
Jul 4, 2026–Jul 31, 20260Within stored history
Aug 1, 2026–Aug 28, 20260Within stored history
Aug 29, 2026–Sep 25, 20260Within stored history
Sep 26, 2026–Oct 23, 2026Latest period0Within stored history
Insider sales · Short history

Only 3 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–3.

Insider sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 25, 2025–Nov 21, 2025—Unavailable
Nov 22, 2025–Dec 19, 2025—Unavailable
Dec 20, 2025–Jan 16, 2026—Unavailable
Jan 17, 2026–Feb 13, 2026—Unavailable
Feb 14, 2026–Mar 13, 2026—Unavailable
Mar 14, 2026–Apr 10, 2026—Unavailable
Apr 11, 2026–May 8, 2026—Unavailable
May 9, 2026–Jun 5, 2026—Unavailable
Jun 6, 2026–Jul 3, 20264Partial; excluded
Jul 4, 2026–Jul 31, 20263Within stored history
Aug 1, 2026–Aug 28, 20260Within stored history
Aug 29, 2026–Sep 25, 20260Within stored history
Sep 26, 2026–Oct 23, 2026Latest period1Within stored history
Congress purchases · Source needs an update

The feed’s newest disclosure is too old for a current comparison. Counts show only the records already stored. Earlier median: —; range: unavailable.

Congress purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 25, 2025–Nov 21, 2025—Unavailable
Nov 22, 2025–Dec 19, 2025—Unavailable
Dec 20, 2025–Jan 16, 2026—Unavailable
Jan 17, 2026–Feb 13, 2026—Unavailable
Feb 14, 2026–Mar 13, 2026—Unavailable
Mar 14, 2026–Apr 10, 2026—Unavailable
Apr 11, 2026–May 8, 2026—Unavailable
May 9, 2026–Jun 5, 2026—Unavailable
Jun 6, 2026–Jul 3, 2026—Unavailable
Jul 4, 2026–Jul 31, 2026—Unavailable
Aug 1, 2026–Aug 28, 2026—Unavailable
Aug 29, 2026–Sep 25, 2026—Unavailable
Sep 26, 2026–Oct 23, 2026Latest period—Unavailable
Congress sales · Source needs an update

The feed’s newest disclosure is too old for a current comparison. Counts show only the records already stored. Earlier median: —; range: unavailable.

Congress sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 25, 2025–Nov 21, 2025—Unavailable
Nov 22, 2025–Dec 19, 2025—Unavailable
Dec 20, 2025–Jan 16, 2026—Unavailable
Jan 17, 2026–Feb 13, 2026—Unavailable
Feb 14, 2026–Mar 13, 2026—Unavailable
Mar 14, 2026–Apr 10, 2026—Unavailable
Apr 11, 2026–May 8, 2026—Unavailable
May 9, 2026–Jun 5, 2026—Unavailable
Jun 6, 2026–Jul 3, 2026—Unavailable
Jul 4, 2026–Jul 31, 2026—Unavailable
Aug 1, 2026–Aug 28, 2026—Unavailable
Aug 29, 2026–Sep 25, 2026—Unavailable
Sep 26, 2026–Oct 23, 2026Latest period—Unavailable
How to read this comparison

The median is the middle count in up to 12 earlier, non-overlapping 28-day periods; the range runs from the smallest to the largest count. The latest period is excluded from both. A comparison needs at least 6 earlier periods, including 3 with activity. The feed’s latest disclosure must be within 7 days of the current period’s end. This freshness check does not verify complete collection.

Insiders include individuals and reporting entities; only purchase and sale codes enter this view. Congress counts reporting members, including their disclosed family transactions. The same filer can appear in purchases and sales, so these categories should not be added into a net count.

These are stored disclosures, not a complete measure of trading. Reporting delays and collection gaps can change the comparison. More activity does not identify a motive or predict a stock’s return.

Company timeline

What has been happening?

May 1, 2026–Oct 16, 2026. Select a month in a category to inspect its records.

Company filings

Insiders

Owners & lobbying

All 26 records in this snapshot
  1. Disclosed
    Matthew Bowen · Sale

    Transaction dated Oct 5, 2026

  2. Filed
  3. Filed
  4. Filed
  5. Filed
  6. Filed
  7. Filed
  8. Disclosed
    Markus Warmuth · Sale

    Transaction dated Jul 16, 2026

  9. Disclosed
    Jennifer Champoux · Sale

    Transaction dated Jul 15, 2026

  10. Filed
  11. Filed
  12. Disclosed
    Sharon Townson · Sale

    Transaction dated Jul 6, 2026

  13. Disclosed
    Sharon Townson · Sale

    Transaction dated Jul 6, 2026

  14. Filed
  15. Disclosed
    Filip Janku · Sale

    Transaction dated Jun 30, 2026

  16. Disclosed
    Anthony M. Manning · Sale

    Transaction dated Jun 29, 2026

  17. Disclosed
    Filip Janku · Sale

    Transaction dated Jun 29, 2026

  18. Filed
  19. Filed
  20. Filed
  21. Disclosed
    Filip Janku · Sale

    Transaction dated Jun 24, 2026

  22. Disclosed
    Filip Janku · Sale

    Transaction dated Jun 23, 2026

  23. Disclosed
    Jennifer Champoux · Sale

    Transaction dated Jun 23, 2026

  24. Disclosed
    Sharon Townson · Sale

    Transaction dated Jun 23, 2026

  25. Disclosed
    Jennifer Champoux · Sale

    Transaction dated Jun 17, 2026

  26. Disclosed
    Sharon Townson · Sale

    Transaction dated Jun 17, 2026

Month counts include every record on file. The lists show the newest records on this page. A dash means none on file that month. Trades use disclosure dates; contract dates follow the source record. Nearby events do not establish the cause of a price move.

Who's buying and selling · last 90 days

Congress

No Congress trades on GLUE disclosed in the last 90 days.

See every Congress trade on GLUE →

Company insiders

0 buys · 1 sell · $137 sold

  1. ▼ SELLMatthew Bowen Principal Accounting OfficerGLUE Monte Rosa Therapeutics, Inc.$137disclosed Oct 6 · filed 1 day after the trade
See every insider trade on GLUE →

Big holders (Schedule 13D / 13G): 1 filing in the last 90 days · newest: Vestal Point Capital, LP (13G), Aug 14, 2026 ↗

Filings & events

Company filings (8-K) 65

Events the company must report to the SEC within days — results, deals, departures, restatements.

What it files 8-Ks about

  • Shared information with investors · item 7.0113
  • Quarterly or yearly results · item 2.029
  • Other events · item 8.018
  • Signed a major agreement · item 1.015
  • Shareholder vote results · item 5.074
  • Directors or officers joined, left or got new pay · item 5.024

Filing red flags 6

Warning signs in the company's own SEC filings — going-concern doubts, control weaknesses, staff comment letters, late filings, restatements, Wells notices, clinical holds, dividend cuts.

Planned insider sales (Form 144) 33

Notices insiders file before they sell certain shares, such as ones they got straight from the company.

None in the last 90 days · 33 notices on file

The notices on file don't give the sale's size; each sale shows up under company insiders once it is reported.

5% owners (13D / 13G) 11

Investors who reported owning 5% or more — 13D for owners who may push for changes, 13G for owners who just hold.

Push for changes, or just hold?

  • 13D, may push for changes: 4 filings
  • 13G, just holds: 7 filings

Filed most: New Enterprise Associates 17, L.P. (2) · Versant Venture Capital VI, L.P. (2) · Vestal Point Capital, LP (1) · TCG Crossover GP II, LLC (1)

Biggest named funds (13F)

The largest GLUE holdings among the well-known funds whose quarterly 13F filings we read — opens here.

Every disclosed trade on GLUE

  1. ▼ SELLMatthew Bowen Principal Accounting OfficerGLUE Monte Rosa Therapeutics, Inc.$137disclosed Oct 6 · filed 1 day after the trade
  2. ▼ SELLMarkus Warmuth President & CEOGLUE Monte Rosa Therapeutics, Inc.$220Kdisclosed Jul 17 · filed 1 day after the trade
  3. ▼ SELLJennifer Champoux Chief Operating OfficerGLUE Monte Rosa Therapeutics, Inc.$102Kdisclosed Jul 16 · filed 1 day after the trade
  4. ▼ SELLSharon Townson Chief Scientific OfficerGLUE Monte Rosa Therapeutics, Inc.$130Kdisclosed Jul 7 · filed 1 day after the trade
  5. ▼ SELLSharon Townson Chief Scientific OfficerGLUE Monte Rosa Therapeutics, Inc.$9.7Kdisclosed Jul 7 · filed 1 day after the trade
  6. ▼ SELLFilip Janku Chief Medical OfficerGLUE Monte Rosa Therapeutics, Inc.$132Kdisclosed Jul 1 · filed 1 day after the trade
  7. ▼ SELLAnthony M. Manning DirectorGLUE Monte Rosa Therapeutics, Inc.$231Kdisclosed Jun 30 · filed 1 day after the trade
  8. ▼ SELLFilip Janku Chief Medical OfficerGLUE Monte Rosa Therapeutics, Inc.$138Kdisclosed Jun 30 · filed 1 day after the trade
  9. ▼ SELLFilip Janku Chief Medical OfficerGLUE Monte Rosa Therapeutics, Inc.$643Kdisclosed Jun 25 · filed 1 day after the trade
  10. ▼ SELLSharon Townson Chief Scientific OfficerGLUE Monte Rosa Therapeutics, Inc.$60Kdisclosed Jun 25 · filed 2 days after the trade
  11. ▼ SELLJennifer Champoux Chief Operating OfficerGLUE Monte Rosa Therapeutics, Inc.$43.5Kdisclosed Jun 25 · filed 2 days after the trade
  12. ▼ SELLFilip Janku Chief Medical OfficerGLUE Monte Rosa Therapeutics, Inc.$240Kdisclosed Jun 25 · filed 2 days after the trade
  13. ▼ SELLJennifer Champoux Chief Operating OfficerGLUE Monte Rosa Therapeutics, Inc.$41.3Kdisclosed Jun 18 · filed 1 day after the trade
  14. ▼ SELLSharon Townson Chief Scientific OfficerGLUE Monte Rosa Therapeutics, Inc.$57Kdisclosed Jun 18 · filed 1 day after the trade
See the trades on GLUE in the feed →
People & votes

Which members of Congress traded GLUE, sponsored bills that touch it and voted on them — opens here.